StockNews.com upgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO – Free Report) from a sell rating to a hold rating in a research note issued to investors on Wednesday. Several other analysts also recently weighed in on AGIO. Royal Bank of Canada reduced their target price on Agios Pharmaceuticals from $43.00 to $42.00 and set an outperform […]
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) – Equities researchers at Zacks Research increased their Q2 2024 earnings per share (EPS) estimates for shares of Agios Pharmaceuticals in a research note issued to investors on Monday, May 20th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will earn ($1.59) per share for […]
Profund Advisors LLC reduced its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 23.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,116 shares of the biopharmaceutical company’s stock after selling 7,028 shares during the quarter. Profund […]
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report) insider James William Burns sold 1,708 shares of Agios Pharmaceuticals stock in a transaction dated Wednesday, January 24th. The stock was sold at an average price of $21.64, for a total value of $36,961.12. Following the completion of the sale, the insider now directly owns 30,378 shares […]
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report) Director Jacqualyn A. Fouse sold 10,722 shares of the business’s stock in a transaction dated Wednesday, January 24th. The stock was sold at an average price of $21.64, for a total transaction of $232,024.08. Following the transaction, the director now owns 129,253 shares in the company, valued […]